
TY  - JOUR
AU  - Satyam, Abhigyan
AU  - Graef, Elizabeth R.
AU  - Lapchak, Peter H.
AU  - Tsokos, Maria G.
AU  - Dalle Lucca, Jurandir J.
AU  - Tsokos, George C.
TI  - Complement and coagulation cascades in trauma
JO  - Acute Medicine & Surgery
JA  - Acute Med Surg
VL  - 6
IS  - 4
SN  - 2052-8817
UR  - https://doi.org/10.1002/ams2.426
DO  - doi:10.1002/ams2.426
SP  - 329
EP  - 335
KW  - Coagulation
KW  - complement
KW  - DAMPs
KW  - PAMPS
KW  - trauma
PY  - 2019
AB  - Trauma remains a major cause of death throughout the world, especially for patients younger than 45 years. Due to rapid advances in clinical management, both in the acute and prehospital settings, trauma patients survive devastating injuries at unprecedented rates. However, these patients can often face life threatening complications that stem from the robust innate immune response induced by severe hemorrhage, leading to further tissue injury rather than repair. The complement and coagulation cascades are key mediators in this disordered reaction, which includes the development of trauma-induced coagulopathy. There is increasing evidence that cross-talk between these two pathways allows rapid amplification of their otherwise targeted responses and contributes to overwhelming and prolonged systemic inflammation. In this article, we summarize the initial steps of innate immune response to trauma and review the complex complement and coagulation cascades, as well as how they interact with each other. Despite progress in understanding these cascades, effective therapeutic targets have yet to be found and further research is needed both to improve survival rates as well as decrease associated morbidity.
ER  - 

AU  - Kobayashi, Leslie
AU  - Hamel, Michelle G.
C7  - pp. 307-315
TI  - Abdominal and Abdominal Vascular Injury
SN  - 9781119317920
UR  - https://doi.org/10.1002/9781119317913.ch31
DO  - doi:10.1002/9781119317913.ch31
SP  - 307-315
KW  - abdominal compartment syndrome
KW  - abdominal vascular injury
KW  - aortic clamping
KW  - damage-control surgery
KW  - intra-abdominal injuries
KW  - nontraumatic abdominal surgery
KW  - pediatric patients
KW  - resuscitative thoracotomy
KW  - seat belt sign
KW  - vascular surgery
PY  - 2019
AB  - Summary This is a unique question-and-answer chapter for surgical residents and trainees, concentrating on the abdominal and abdominal vascular injury. The presence of a seat belt sign (SBS) on the abdomen is associated with a significant increase in intra-abdominal injuries. In adult populations, the presence of an SBS increases the risk of intra-abdominal injury twofold to eightfold. An SBS may be even more concerning in pediatric patients where rates of intra-abdominal injury can be increased as much as twelvefold. Damage-control surgery (DCS) has been applied to many surgical conditions including nontraumatic abdominal surgery, vascular surgery, and orthopedic surgery. For the trauma patient in extremis with noncompressible abdominal or pelvic hemorrhage, resuscitative endovascular balloon occlusion of the aorta (REBOA) is gaining popularity as an alternative to resuscitative thoracotomy and aortic clamping. Abdominal compartment syndrome can affect many body systems including neurologic, cardiac, pulmonary, gastrointestinal, hepatic, and genitourinary.
ER  - 

TY  - JOUR
AU  - Miko, Iren
AU  - Brath, Endre
AU  - Nemeth, Norbert
AU  - Toth, Ferenc F.
AU  - Sipka, Sandor
AU  - Kovacs, Judit
AU  - Sipka Jr., Sandor
AU  - Fachet, Jozsef
AU  - Furka, Andrea
AU  - Furka, Istvan
AU  - Zhong, Robert
TI  - Hematological, hemorheological, immunological, and morphological studies of spleen autotransplantation in mice: Preliminary results
JO  - Microsurgery
JA  - Microsurgery
VL  - 23
IS  - 5
SN  - 9781119317920
UR  - https://doi.org/10.1002/micr.10166
DO  - doi:10.1002/micr.10166
SP  - 483
EP  - 488
PY  - 2003
AB  - Abstract Using a spleen autotransplantation model, we conducted hematological, hemorheological, immunological, and morphological studies in mice 6 weeks after splenectomy. Sixty male and female A/J inbred mice were equally divided into 3 groups: 1) SE group, splenectomy was performed; 2) AU group, spleen chips were autotransplanted into the omentum without vascular anastomosis following splenectomy; and 3) C group (controls), no intervention in these mice. At postoperative week 6, the following studies were performed: 1) measurement of hematological parameters; 2) hemorheological studies, including relative cell transit time (RCTT) and fibrinogen levels; and 3) activity of peripheral phagocytes, measured by zymozan-induced chemiluminescence, which was calculated in stimulation index values (SI). In addition, histological investigations of autotransplants were conducted. Erythrocyte mean cell volume and platelet counts, RCTT, fibrinogen levels, and activity of phagocytes were significantly higher in the SE group, compared to those in the C group. In the AU group, these parameters were similar to those in the C group. Morphologically, the transplanted spleen showed normal histology. These data indicate that the transplanted spleens restored their function. We conclude that spleen autotransplantation reserves the normal morphology of spleen and restores most of the spleen's hematological, hemorheological, and immunological functions. Both SI index and erythrocyte deformability can be an informative detection of decreasing splenic function. These data suggest that spleen autotransplantation may provide a useful tool to prevent complications following splenectomy in a clinical setting. Lép autotransplantatios egér modellen a 6. posztoperatív héten haematologiai, haemorheologiai, immunologiai és morphologiai vizsgálatokat végeztünk splenectomiát követ?en. Hatvan A/J inbred egeret 3 egyenl? csoportba osztottunk: 1) SE csoport: splenectomia, 2) AU csoport: splenectomiát követ?en lép-chip autotransplantatio a cseplesz kett?zetébe éranastomosis nélkül, 3) C csoport?control: sebészi beavatkozás nem történt. A 6. posztoperatív héten 1) haematologiai paraméterek meghatározása, 2) a haemorheologiai vizsgálatként a vörösvérsejt deformabilitás mérése (relatív sejttranzit-id?, RCTT), a fibrinogén szint meghatározása történt, 3) immunologiai mérömódszerként a perifériás phagocyták aktivitását zymosan függ? chemiluminescentiával mértük, a stimulációs index (SI) számításával. Párhuzamosan az autotransplantált lép-chipek szövettani értékelését is elvégeztük. Az erythrocyták átlagos térfogata és a thrombocyták száma, az RCTT és a fibrinogén szint, valamint a phagocyták aktivitása szignifikánsan nagyobb volt az SE, mint a C csoportban. Ezek a paraméterek az AU csoportban hasonlóak voltak a C csoport értékeihez. Az autotransplantált lépek normális histologiájú képet mutattak. Eredményeink azt sugallják, hogy a transplantalt lép-chipek funkciója helyreállt. Kísérleteink alapján úgy t?nik, hogy a lép autotransplantatio meg?rzi a lépszövet normál morphologiáját, nagyrészt helyreállítja a haematologiai, haemorheologiai és immunologiai funkciókat. A lépfunkció csökkenésének érzékeny jelz?je lehet az SI és a vörösvérsejt deformabilitás értékeinek változása. Adataink szerint a lépautotransplantatio hatékony eszköz lehet a splenctomiákat követ? komplikációk megel?zésében a klinikai gyakorlatban is. ? 2003 Wiley-Liss, Inc. MICROSURGERY 23:483?488 2003
ER  - 

TY  - JOUR
AU  - Ekdahl, Kristina N.
AU  - Teramura, Yuji
AU  - Hamad, Osama A.
AU  - Asif, Sana
AU  - Duehrkop, Claudia
AU  - Fromell, Karin
AU  - Gustafson, Elisabet
AU  - Hong, Jaan
AU  - Kozarcanin, Huda
AU  - Magnusson, Peetra U.
AU  - Huber-Lang, Markus
AU  - Garred, Peter
AU  - Nilsson, Bo
TI  - Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation
JO  - Immunological Reviews
JA  - Immunol Rev
VL  - 274
IS  - 1
SN  - 9781119317920
UR  - https://doi.org/10.1111/imr.12471
DO  - doi:10.1111/imr.12471
SP  - 245
EP  - 269
KW  - coagulation
KW  - complement system
KW  - contact activation/kallikrein system
KW  - innate immunity
KW  - platelets
KW  - thromboinflammation
PY  - 2016
AB  - Summary Innate immunity is fundamental to our defense against microorganisms. Physiologically, the intravascular innate immune system acts as a purging system that identifies and removes foreign substances leading to thromboinflammatory responses, tissue remodeling, and repair. It is also a key contributor to the adverse effects observed in many diseases and therapies involving biomaterials and therapeutic cells/organs. The intravascular innate immune system consists of the cascade systems of the blood (the complement, contact, coagulation, and fibrinolytic systems), the blood cells (polymorphonuclear cells, monocytes, platelets), and the endothelial cell lining of the vessels. Activation of the intravascular innate immune system in vivo leads to thromboinflammation that can be activated by several of the system's pathways and that initiates repair after tissue damage and leads to adverse reactions in several disorders and treatment modalities. In this review, we summarize the current knowledge in the field and discuss the obstacles that exist in order to study the cross-talk between the components of the intravascular innate immune system. These include the use of purified in vitro systems, animal models and various types of anticoagulants. In order to avoid some of these obstacles we have developed specialized human whole blood models that allow investigation of the cross-talk between the various cascade systems and the blood cells. We in particular stress that platelets are involved in these interactions and that the lectin pathway of the complement system is an emerging part of innate immunity that interacts with the contact/coagulation system. Understanding the resulting thromboinflammation will allow development of new therapeutic modalities.
ER  - 

TY  - JOUR
AU  - Wood, Alexander J. T.
AU  - Vassallo, Arlette
AU  - Summers, Charlotte
AU  - Chilvers, Edwin R.
AU  - Conway-Morris, Andrew
C7  - e13028
TI  - C5a anaphylatoxin and its role in critical illness-induced organ dysfunction
JO  - European Journal of Clinical Investigation
JA  - Eur J Clin Invest
VL  - 48
IS  - 12
SN  - 9781119317920
UR  - https://doi.org/10.1111/eci.13028
DO  - doi:10.1111/eci.13028
SP  - e13028
KW  - C5a
KW  - complement
KW  - critical illness
KW  - immunosuppression
KW  - infection
KW  - neutrophil
PY  - 2018
AB  - Abstract Critical illness is an aetiologically and clinically heterogeneous syndrome that is characterised by organ failure and immune dysfunction. Mortality in critically ill patients is driven by inflammation-associated organ damage and a profound vulnerability to nosocomial infection. Both factors are influenced by the activated complement protein C5a, released by unbridled activation of the complement system during critical illness. C5a exerts deleterious effects on organ systems directly and suppresses antimicrobial functions of key immune cells. Whilst several recent reports have added key knowledge of the cellular signalling pathways triggered by C5a, there remain a number of areas that are incompletely understood and therapeutic opportunities are still being evaluated. In this review, we summarise the cellular basis for C5a-induced vulnerability to nosocomial infection and organ dysfunction. We focus on cells of the innate immune system, highlighting the major areas in need of further research and potential avenues for targeted therapies.
ER  - 

TY  - JOUR
AU  - Cossarizza, Andrea
AU  - Chang, Hyun-Dong
AU  - Radbruch, Andreas
AU  - Acs, Andreas
AU  - Adam, Dieter
AU  - Adam-Klages, Sabine
AU  - Agace, William W.
AU  - Aghaeepour, Nima
AU  - Akdis, Mübeccel
AU  - Allez, Matthieu
AU  - Almeida, Larissa Nogueira
AU  - Alvisi, Giorgia
AU  - Anderson, Graham
AU  - Andrä, Immanuel
AU  - Annunziato, Francesco
AU  - Anselmo, Achille
AU  - Bacher, Petra
AU  - Baldari, Cosima T.
AU  - Bari, Sudipto
AU  - Barnaba, Vincenzo
AU  - Barros-Martins, Joana
AU  - Battistini, Luca
AU  - Bauer, Wolfgang
AU  - Baumgart, Sabine
AU  - Baumgarth, Nicole
AU  - Baumjohann, Dirk
AU  - Baying, Bianka
AU  - Bebawy, Mary
AU  - Becher, Burkhard
AU  - Beisker, Wolfgang
AU  - Benes, Vladimir
AU  - Beyaert, Rudi
AU  - Blanco, Alfonso
AU  - Boardman, Dominic A.
AU  - Bogdan, Christian
AU  - Borger, Jessica G.
AU  - Borsellino, Giovanna
AU  - Boulais, Philip E.
AU  - Bradford, Jolene A.
AU  - Brenner, Dirk
AU  - Brinkman, Ryan R.
AU  - Brooks, Anna E. S.
AU  - Busch, Dirk H.
AU  - Büscher, Martin
AU  - Bushnell, Timothy P.
AU  - Calzetti, Federica
AU  - Cameron, Garth
AU  - Cammarata, Ilenia
AU  - Cao, Xuetao
AU  - Cardell, Susanna L.
AU  - Casola, Stefano
AU  - Cassatella, Marco A.
AU  - Cavani, Andrea
AU  - Celada, Antonio
AU  - Chatenoud, Lucienne
AU  - Chattopadhyay, Pratip K.
AU  - Chow, Sue
AU  - Christakou, Eleni
AU  - Čičin-Šain, Luka
AU  - Clerici, Mario
AU  - Colombo, Federico S.
AU  - Cook, Laura
AU  - Cooke, Anne
AU  - Cooper, Andrea M.
AU  - Corbett, Alexandra J.
AU  - Cosma, Antonio
AU  - Cosmi, Lorenzo
AU  - Coulie, Pierre G.
AU  - Cumano, Ana
AU  - Cvetkovic, Ljiljana
AU  - Dang, Van Duc
AU  - Dang-Heine, Chantip
AU  - Davey, Martin S.
AU  - Davies, Derek
AU  - De Biasi, Sara
AU  - Del Zotto, Genny
AU  - Dela Cruz, Gelo Victoriano
AU  - Delacher, Michael
AU  - Della Bella, Silvia
AU  - Dellabona, Paolo
AU  - Deniz, Günnur
AU  - Dessing, Mark
AU  - Di Santo, James P.
AU  - Diefenbach, Andreas
AU  - Dieli, Francesco
AU  - Dolf, Andreas
AU  - Dörner, Thomas
AU  - Dress, Regine J.
AU  - Dudziak, Diana
AU  - Dustin, Michael
AU  - Dutertre, Charles-Antoine
AU  - Ebner, Friederike
AU  - Eckle, Sidonia B. G.
AU  - Edinger, Matthias
AU  - Eede, Pascale
AU  - Ehrhardt, Götz R.A.
AU  - Eich, Marcus
AU  - Engel, Pablo
AU  - Engelhardt, Britta
AU  - Erdei, Anna
AU  - Esser, Charlotte
AU  - Everts, Bart
AU  - Evrard, Maximilien
AU  - Falk, Christine S.
AU  - Fehniger, Todd A.
AU  - Felipo-Benavent, Mar
AU  - Ferry, Helen
AU  - Feuerer, Markus
AU  - Filby, Andrew
AU  - Filkor, Kata
AU  - Fillatreau, Simon
AU  - Follo, Marie
AU  - Förster, Irmgard
AU  - Foster, John
AU  - Foulds, Gemma A.
AU  - Frehse, Britta
AU  - Frenette, Paul S.
AU  - Frischbutter, Stefan
AU  - Fritzsche, Wolfgang
AU  - Galbraith, David W.
AU  - Gangaev, Anastasia
AU  - Garbi, Natalio
AU  - Gaudilliere, Brice
AU  - Gazzinelli, Ricardo T.
AU  - Geginat, Jens
AU  - Gerner, Wilhelm
AU  - Gherardin, Nicholas A.
AU  - Ghoreschi, Kamran
AU  - Gibellini, Lara
AU  - Ginhoux, Florent
AU  - Goda, Keisuke
AU  - Godfrey, Dale I.
AU  - Goettlinger, Christoph
AU  - González-Navajas, Jose M.
AU  - Goodyear, Carl S.
AU  - Gori, Andrea
AU  - Grogan, Jane L.
AU  - Grummitt, Daryl
AU  - Grützkau, Andreas
AU  - Haftmann, Claudia
AU  - Hahn, Jonas
AU  - Hammad, Hamida
AU  - Hämmerling, Günter
AU  - Hansmann, Leo
AU  - Hansson, Goran
AU  - Harpur, Christopher M.
AU  - Hartmann, Susanne
AU  - Hauser, Andrea
AU  - Hauser, Anja E.
AU  - Haviland, David L.
AU  - Hedley, David
AU  - Hernández, Daniela C.
AU  - Herrera, Guadalupe
AU  - Herrmann, Martin
AU  - Hess, Christoph
AU  - Höfer, Thomas
AU  - Hoffmann, Petra
AU  - Hogquist, Kristin
AU  - Holland, Tristan
AU  - Höllt, Thomas
AU  - Holmdahl, Rikard
AU  - Hombrink, Pleun
AU  - Houston, Jessica P.
AU  - Hoyer, Bimba F.
AU  - Huang, Bo
AU  - Huang, Fang-Ping
AU  - Huber, Johanna E.
AU  - Huehn, Jochen
AU  - Hundemer, Michael
AU  - Hunter, Christopher A.
AU  - Hwang, William Y. K.
AU  - Iannone, Anna
AU  - Ingelfinger, Florian
AU  - Ivison, Sabine M
AU  - Jäck, Hans-Martin
AU  - Jani, Peter K.
AU  - Jávega, Beatriz
AU  - Jonjic, Stipan
AU  - Kaiser, Toralf
AU  - Kalina, Tomas
AU  - Kamradt, Thomas
AU  - Kaufmann, Stefan H. E.
AU  - Keller, Baerbel
AU  - Ketelaars, Steven L. C.
AU  - Khalilnezhad, Ahad
AU  - Khan, Srijit
AU  - Kisielow, Jan
AU  - Klenerman, Paul
AU  - Knopf, Jasmin
AU  - Koay, Hui-Fern
AU  - Kobow, Katja
AU  - Kolls, Jay K.
AU  - Kong, Wan Ting
AU  - Kopf, Manfred
AU  - Korn, Thomas
AU  - Kriegsmann, Katharina
AU  - Kristyanto, Hendy
AU  - Kroneis, Thomas
AU  - Krueger, Andreas
AU  - Kühne, Jenny
AU  - Kukat, Christian
AU  - Kunkel, Désirée
AU  - Kunze-Schumacher, Heike
AU  - Kurosaki, Tomohiro
AU  - Kurts, Christian
AU  - Kvistborg, Pia
AU  - Kwok, Immanuel
AU  - Landry, Jonathan
AU  - Lantz, Olivier
AU  - Lanuti, Paola
AU  - LaRosa, Francesca
AU  - Lehuen, Agnès
AU  - LeibundGut-Landmann, Salomé
AU  - Leipold, Michael D.
AU  - Leung, Leslie Y.T.
AU  - Levings, Megan K.
AU  - Lino, Andreia C.
AU  - Liotta, Francesco
AU  - Litwin, Virginia
AU  - Liu, Yanling
AU  - Ljunggren, Hans-Gustaf
AU  - Lohoff, Michael
AU  - Lombardi, Giovanna
AU  - Lopez, Lilly
AU  - López-Botet, Miguel
AU  - Lovett-Racke, Amy E.
AU  - Lubberts, Erik
AU  - Luche, Herve
AU  - Ludewig, Burkhard
AU  - Lugli, Enrico
AU  - Lunemann, Sebastian
AU  - Maecker, Holden T.
AU  - Maggi, Laura
AU  - Maguire, Orla
AU  - Mair, Florian
AU  - Mair, Kerstin H.
AU  - Mantovani, Alberto
AU  - Manz, Rudolf A.
AU  - Marshall, Aaron J.
AU  - Martínez-Romero, Alicia
AU  - Martrus, Glòria
AU  - Marventano, Ivana
AU  - Maslinski, Wlodzimierz
AU  - Matarese, Giuseppe
AU  - Mattioli, Anna Vittoria
AU  - Maueröder, Christian
AU  - Mazzoni, Alessio
AU  - McCluskey, James
AU  - McGrath, Mairi
AU  - McGuire, Helen M.
AU  - McInnes, Iain B.
AU  - Mei, Henrik E.
AU  - Melchers, Fritz
AU  - Melzer, Susanne
AU  - Mielenz, Dirk
AU  - Miller, Stephen D.
AU  - Mills, Kingston H.G.
AU  - Minderman, Hans
AU  - Mjösberg, Jenny
AU  - Moore, Jonni
AU  - Moran, Barry
AU  - Moretta, Lorenzo
AU  - Mosmann, Tim R.
AU  - Müller, Susann
AU  - Multhoff, Gabriele
AU  - Muñoz, Luis Enrique
AU  - Münz, Christian
AU  - Nakayama, Toshinori
AU  - Nasi, Milena
AU  - Neumann, Katrin
AU  - Ng, Lai Guan
AU  - Niedobitek, Antonia
AU  - Nourshargh, Sussan
AU  - Núñez, Gabriel
AU  - O'Connor, José-Enrique
AU  - Ochel, Aaron
AU  - Oja, Anna
AU  - Ordonez, Diana
AU  - Orfao, Alberto
AU  - Orlowski-Oliver, Eva
AU  - Ouyang, Wenjun
AU  - Oxenius, Annette
AU  - Palankar, Raghavendra
AU  - Panse, Isabel
AU  - Pattanapanyasat, Kovit
AU  - Paulsen, Malte
AU  - Pavlinic, Dinko
AU  - Penter, Livius
AU  - Peterson, Pärt
AU  - Peth, Christian
AU  - Petriz, Jordi
AU  - Piancone, Federica
AU  - Pickl, Winfried F.
AU  - Piconese, Silvia
AU  - Pinti, Marcello
AU  - Pockley, A. Graham
AU  - Podolska, Malgorzata Justyna
AU  - Poon, Zhiyong
AU  - Pracht, Katharina
AU  - Prinz, Immo
AU  - Pucillo, Carlo E. M.
AU  - Quataert, Sally A.
AU  - Quatrini, Linda
AU  - Quinn, Kylie M.
AU  - Radbruch, Helena
AU  - Radstake, Tim R. D. J.
AU  - Rahmig, Susann
AU  - Rahn, Hans-Peter
AU  - Rajwa, Bartek
AU  - Ravichandran, Gevitha
AU  - Raz, Yotam
AU  - Rebhahn, Jonathan A.
AU  - Recktenwald, Diether
AU  - Reimer, Dorothea
AU  - Reis e Sousa, Caetano
AU  - Remmerswaal, Ester B.M.
AU  - Richter, Lisa
AU  - Rico, Laura G.
AU  - Riddell, Andy
AU  - Rieger, Aja M.
AU  - Robinson, J. Paul
AU  - Romagnani, Chiara
AU  - Rubartelli, Anna
AU  - Ruland, Jürgen
AU  - Saalmüller, Armin
AU  - Saeys, Yvan
AU  - Saito, Takashi
AU  - Sakaguchi, Shimon
AU  - Sala-de-Oyanguren, Francisco
AU  - Samstag, Yvonne
AU  - Sanderson, Sharon
AU  - Sandrock, Inga
AU  - Santoni, Angela
AU  - Sanz, Ramon Bellmàs
AU  - Saresella, Marina
AU  - Sautes-Fridman, Catherine
AU  - Sawitzki, Birgit
AU  - Schadt, Linda
AU  - Scheffold, Alexander
AU  - Scherer, Hans U.
AU  - Schiemann, Matthias
AU  - Schildberg, Frank A.
AU  - Schimisky, Esther
AU  - Schlitzer, Andreas
AU  - Schlosser, Josephine
AU  - Schmid, Stephan
AU  - Schmitt, Steffen
AU  - Schober, Kilian
AU  - Schraivogel, Daniel
AU  - Schuh, Wolfgang
AU  - Schüler, Thomas
AU  - Schulte, Reiner
AU  - Schulz, Axel Ronald
AU  - Schulz, Sebastian R.
AU  - Scottá, Cristiano
AU  - Scott-Algara, Daniel
AU  - Sester, David P.
AU  - Shankey, T. Vincent
AU  - Silva-Santos, Bruno
AU  - Simon, Anna Katharina
AU  - Sitnik, Katarzyna M.
AU  - Sozzani, Silvano
AU  - Speiser, Daniel E.
AU  - Spidlen, Josef
AU  - Stahlberg, Anders
AU  - Stall, Alan M.
AU  - Stanley, Natalie
AU  - Stark, Regina
AU  - Stehle, Christina
AU  - Steinmetz, Tobit
AU  - Stockinger, Hannes
AU  - Takahama, Yousuke
AU  - Takeda, Kiyoshi
AU  - Tan, Leonard
AU  - Tárnok, Attila
AU  - Tiegs, Gisa
AU  - Toldi, Gergely
AU  - Tornack, Julia
AU  - Traggiai, Elisabetta
AU  - Trebak, Mohamed
AU  - Tree, Timothy I.M.
AU  - Trotter, Joe
AU  - Trowsdale, John
AU  - Tsoumakidou, Maria
AU  - Ulrich, Henning
AU  - Urbanczyk, Sophia
AU  - van de Veen, Willem
AU  - van den Broek, Maries
AU  - van der Pol, Edwin
AU  - Van Gassen, Sofie
AU  - Van Isterdael, Gert
AU  - van Lier, René A.W.
AU  - Veldhoen, Marc
AU  - Vento-Asturias, Salvador
AU  - Vieira, Paulo
AU  - Voehringer, David
AU  - Volk, Hans-Dieter
AU  - von Borstel, Anouk
AU  - von Volkmann, Konrad
AU  - Waisman, Ari
AU  - Walker, Rachael V.
AU  - Wallace, Paul K.
AU  - Wang, Sa A.
AU  - Wang, Xin M.
AU  - Ward, Michael D.
AU  - Ward-Hartstonge, Kirsten A
AU  - Warnatz, Klaus
AU  - Warnes, Gary
AU  - Warth, Sarah
AU  - Waskow, Claudia
AU  - Watson, James V.
AU  - Watzl, Carsten
AU  - Wegener, Leonie
AU  - Weisenburger, Thomas
AU  - Wiedemann, Annika
AU  - Wienands, Jürgen
AU  - Wilharm, Anneke
AU  - Wilkinson, Robert John
AU  - Willimsky, Gerald
AU  - Wing, James B.
AU  - Winkelmann, Rieke
AU  - Winkler, Thomas H.
AU  - Wirz, Oliver F.
AU  - Wong, Alicia
AU  - Wurst, Peter
AU  - Yang, Jennie H. M.
AU  - Yang, Juhao
AU  - Yazdanbakhsh, Maria
AU  - Yu, Liping
AU  - Yue, Alice
AU  - Zhang, Hanlin
AU  - Zhao, Yi
AU  - Ziegler, Susanne Maria
AU  - Zielinski, Christina
AU  - Zimmermann, Jakob
AU  - Zychlinsky, Arturo
TI  - Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
JO  - European Journal of Immunology
JA  - Eur. J. Immunol.
VL  - 49
IS  - 10
SN  - 9781119317920
UR  - https://doi.org/10.1002/eji.201970107
DO  - doi:10.1002/eji.201970107
SP  - 1457
EP  - 1973
PY  - 2019
AB  - Abstract These guidelines are a consensus work of a considerable number of members of the immunology and flow cytometry community. They provide the theory and key practical aspects of flow cytometry enabling immunologists to avoid the common errors that often undermine immunological data. Notably, there are comprehensive sections of all major immune cell types with helpful Tables detailing phenotypes in murine and human cells. The latest flow cytometry techniques and applications are also described, featuring examples of the data that can be generated and, importantly, how the data can be analysed. Furthermore, there are sections detailing tips, tricks and pitfalls to avoid, all written and peer-reviewed by leading experts in the field, making this an essential research companion.
ER  - 

TY  - JOUR
AU  - Delgado-Escueta, Antonio V.
AU  - Greenberg, David A.
AU  - Treiman, Lucy
AU  - Liu, Amy
AU  - Sparkes, Robert S.
AU  - Barbetti, Aida
AU  - Park, Min Sik
AU  - Terasaki, Paul I.
TI  - Mapping the Gene for Juvenile Myoclonic Epilepsy
JO  - Epilepsia
VL  - 30
IS  - s4
SN  - 9781119317920
UR  - https://doi.org/10.1111/j.1528-1157.1989.tb05835.x
DO  - doi:10.1111/j.1528-1157.1989.tb05835.x
SP  - S8
EP  - S18
KW  - Epilepsy
KW  - Juvenile myoclonic epilepsy
KW  - Genetics
KW  - Linkage
KW  - Human leukocyte antigen
PY  - 1989
AB  - Summary: The practice of epileptology at a molecular level, where gene products are identified by gene mapping, will soon be possible for a growing number of epilepsies. Juvenile myoclonic epilepsy (JME) is the first of such epilepsies to be mapped to a chromosome, namely chromosome 6p21.3. Family studies of 68 JME probands from California revealed 50% of all families reported seizures in first- or second-degree relatives. Twelve percent of all family members other than the proband had epileptic seizures. Eighty percent of symptomatic siblings and 6% of asymptomatic siblings had diffuse 4- to 6-Hz multi-spike-wave complexes. Twelve percent of asymptomatic parents had diffuse, nonspecific slow waves mixed with spikes or sharp waves. JME is tightly linked to the Bf-HLA loci in chromosome 6. No matter what mode of inheritance is assumed, linkage to the clinical manifestations of JME and its associated EEG traits is indicated by lod scores over 3.0, as long as ?EEG affected? but clinically asymptomatic family members are counted as affected during LIPED analysis. Studies are now being done to further localize the JME site. At the same time, further linkage studies should decide if JME is heterogeneous within itself and whether the same JME site in 6p21.3 underlies absence and grand mal epilepsies.
ER  - 

TY  - JOUR
AU  - Holers, V. Michael
TI  - The spectrum of complement alternative pathway-mediated diseases
JO  - Immunological Reviews
VL  - 223
IS  - 1
SN  - 9781119317920
UR  - https://doi.org/10.1111/j.1600-065X.2008.00641.x
DO  - doi:10.1111/j.1600-065X.2008.00641.x
SP  - 300
EP  - 316
KW  - complement
KW  - inhibitors
KW  - complement deficiency
KW  - genetics
PY  - 2008
AB  - Summary: The complement system has once again come into prominence in the therapeutic development arena. The recent approval of an inhibitory monoclonal antibody, eculizumab, which is directed against complement component C5 for the disease paroxysmal nocturnal hemoglobinuria has provided the initial validation of this system as a therapeutic target. Preclinical studies using animal models and human-derived samples demonstrate that inhibition of complement ameliorates many inflammatory and autoimmune disease manifestations. Major efforts continue to define the most optimal means to block complement activation in a cost-effective manner. Because the system is initiated through three pathways and generates at least six immunoregulatory and pro-inflammatory mediators, there is substantial complexity to this problem. One pathway, designated the alternative pathway, has recently been shown to play a particularly important role in preclinical disease models. Further evidence of the importance of the alternative pathway has been provided by studies of human diseases, where mutations or dysfunctional polymorphisms that promote activation of this pathway are highly associated with the diseases atypical hemolytic uremic syndrome, dense deposit disease, and age-related macular degeneration. This article reviews evidence in support of the essential role of the alternative pathway in the generation of tissue injury and the rationale for development of therapies that modulate its activity.
ER  - 

TY  - JOUR
AU  - Mastellos, Dimitrios C.
AU  - Yancopoulou, Despina
AU  - Kokkinos, Petros
AU  - Huber-Lang, Markus
AU  - Hajishengallis, George
AU  - Biglarnia, Ali R.
AU  - Lupu, Florea
AU  - Nilsson, Bo
AU  - Risitano, Antonio M.
AU  - Ricklin, Daniel
AU  - Lambris, John D.
TI  - Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention
JO  - European Journal of Clinical Investigation
JA  - Eur J Clin Invest
VL  - 45
IS  - 4
SN  - 9781119317920
UR  - https://doi.org/10.1111/eci.12419
DO  - doi:10.1111/eci.12419
SP  - 423
EP  - 440
KW  - clinical translation
KW  - complement-based drug design
KW  - compstatin
KW  - Cp40
KW  - nonhuman primate models
KW  - peptidic C3 inhibitors
PY  - 2015
AB  - Abstract There is a growing awareness that complement plays an integral role in human physiology and disease, transcending its traditional perception as an accessory system for pathogen clearance and opsonic cell killing. As the list of pathologies linked to dysregulated complement activation grows longer, it has become clear that targeted modulation of this innate immune system opens new windows of therapeutic opportunity for anti-inflammatory drug design. Indeed, the introduction of the first complement-targeting drugs has reignited a vibrant interest in the clinical translation of complement-based inhibitors. Compstatin was discovered as a cyclic peptide that inhibits complement activation by binding C3 and interfering with convertase formation and C3 cleavage. As the convergence point of all activation pathways and a molecular hub for crosstalk with multiple pathogenic pathways, C3 represents an attractive target for therapeutic modulation of the complement cascade. A multidisciplinary drug optimization effort encompassing rational ?wet? and in silico synthetic approaches and an array of biophysical, structural and analytical tools has culminated in an impressive structure-function refinement of compstatin, yielding a series of analogues that show promise for a wide spectrum of clinical applications. These new derivatives have improved inhibitory potency and pharmacokinetic profiles and show efficacy in clinically relevant primate models of disease. This review provides an up-to-date survey of the drug design effort placed on the compstatin family of C3 inhibitors, highlighting the most promising drug candidates. It also discusses translational challenges in complement drug discovery and peptide drug development and reviews concerns related to systemic C3 interception.
ER  - 

TY  - JOUR
AU  - Daigo, Kenji
AU  - Inforzato, Antonio
AU  - Barajon, Isabella
AU  - Garlanda, Cecilia
AU  - Bottazzi, Barbara
AU  - Meri, Seppo
AU  - Mantovani, Alberto
TI  - Pentraxins in the activation and regulation of innate immunity
JO  - Immunological Reviews
JA  - Immunol Rev
VL  - 274
IS  - 1
SN  - 9781119317920
UR  - https://doi.org/10.1111/imr.12476
DO  - doi:10.1111/imr.12476
SP  - 202
EP  - 217
KW  - cancer-related inflammation
KW  - complement activation
KW  - inflammation
KW  - opsonization
KW  - pentraxins
KW  - PTX3
PY  - 2016
AB  - Summary Humoral fluid phase pattern recognition molecules (PRMs) are a key component of the activation and regulation of innate immunity. Humoral PRMs are diverse. We focused on the long pentraxin PTX3 as a paradigmatic example of fluid phase PRMs. PTX3 acts as a functional ancestor of antibodies and plays a non-redundant role in resistance against selected microbes in mouse and man and in the regulation of inflammation. This molecule interacts with complement components, thus modulating complement activation. In particular, PTX3 regulates complement-driven macrophage-mediated tumor progression, acting as an extrinsic oncosuppressor in preclinical models and selected human tumors. Evidence collected over the years suggests that PTX3 is a biomarker and potential therapeutic agent in humans, and pave the way to translation of this molecule into the clinic.
ER  - 

AU  - Morgan, B. Paul
TI  - Complement
SN  - 9780470686386
UR  - https://doi.org/10.1002/9780470688618.taw0090
DO  - doi:10.1002/9780470688618.taw0090
KW  - complement (C), component of innate immunity and pathogen defense
KW  - C system component proteins
KW  - constituent pathways of C system and component proteins in sequential order
KW  - classical pathway activation
KW  - alternative pathway activation efficiency and low-level or ‘tickover’ activation
KW  - membrane attack pathway
KW  - role of C in apoptosis
KW  - complement therapies, manipulating C system therapeutically in diseases
PY  - 2016
AB  - Abstract
ER  - 

TY  - JOUR
TI  - Posters Abstracts
JO  - Research and Practice in Thrombosis and Haemostasis
JA  - Res Pract Thromb Haemost
VL  - 3
IS  - S1
SN  - 9780470686386
UR  - https://doi.org/10.1002/rth2.12229
DO  - doi:10.1002/rth2.12229
SP  - 1
EP  - 891
PY  - 2019
ER  - 

C7  - pp. 454-461
TI  - Index
SN  - 9780470654613
UR  - https://doi.org/10.1002/9781118274231.index
DO  - doi:10.1002/9781118274231.index
SP  - 454-461
PY  - 2019
ER  - 

TY  - JOUR
AU  - Jenks, Peter J.
AU  - Jones, Eleri
TI  - Infections in asplenic patients
JO  - Clinical Microbiology and Infection
VL  - 1
IS  - 4
SN  - 9780470654613
UR  - https://doi.org/10.1111/j.1469-0691.1996.tb00573.x
DO  - doi:10.1111/j.1469-0691.1996.tb00573.x
SP  - 266
EP  - 272
PY  - 1996
ER  - 

TY  - JOUR
TI  - Poster Session
JO  - European Journal of Immunology
JA  - Eur. J. Immunol.
VL  - 39
IS  - S1
SN  - 9780470654613
UR  - https://doi.org/10.1002/eji.200990286
DO  - doi:10.1002/eji.200990286
SP  - S624
EP  - S760
PY  - 2009
AB  - Abstract No Abtract
ER  - 

TY  - JOUR
TI  - PRIMARY IMMUNODEFICIENCY DISEASES
JO  - Clinical & Experimental Immunology
VL  - 99
IS  - s1
SN  - 9780470654613
UR  - https://doi.org/10.1111/j.1365-2249.1995.tb06258.x
DO  - doi:10.1111/j.1365-2249.1995.tb06258.x
SP  - 2
EP  - 24
PY  - 1995
ER  - 

TY  - JOUR
AU  - Fossati, Giuliana
AU  - Pozzi, Davide
AU  - Canzi, Alice
AU  - Mirabella, Filippo
AU  - Valentino, Sonia
AU  - Morini, Raffaella
AU  - Ghirardini, Elsa
AU  - Filipello, Fabia
AU  - Moretti, Milena
AU  - Gotti, Cecilia
AU  - Annis, Douglas S
AU  - Mosher, Deane F
AU  - Garlanda, Cecilia
AU  - Bottazzi, Barbara
AU  - Taraboletti, Giulia
AU  - Mantovani, Alberto
AU  - Matteoli, Michela
AU  - Menna, Elisabetta
C7  - e99529
TI  - Pentraxin 3 regulates synaptic function by inducing AMPA receptor clustering via ECM remodeling and β1-integrin
JO  - The EMBO Journal
JA  - EMBO J
VL  - 38
IS  - 1
SN  - 9780470654613
UR  - https://doi.org/10.15252/embj.201899529
DO  - doi:10.15252/embj.201899529
SP  - e99529
KW  - AMPARs
KW  - astrocyte
KW  - PTX3
KW  - synapse
KW  - thrombospondin
PY  - 2019
AB  - Abstract Control of synapse number and function in the developing central nervous system is critical to the formation of neural circuits. Astrocytes play a key role in this process by releasing factors that promote the formation of excitatory synapses. Astrocyte-secreted thrombospondins (TSPs) induce the formation of structural synapses, which however remain post-synaptically silent, suggesting that completion of early synaptogenesis may require a two-step mechanism. Here, we show that the humoral innate immune molecule Pentraxin 3 (PTX3) is expressed in the developing rodent brain. PTX3 plays a key role in promoting functionally-active CNS synapses, by increasing the surface levels and synaptic clustering of AMPA glutamate receptors. This process involves tumor necrosis factor-induced protein 6 (TSG6), remodeling of the perineuronal network, and a ?1-integrin/ERK pathway. Furthermore, PTX3 activity is regulated by TSP1, which directly interacts with the N-terminal region of PTX3. These data unveil a fundamental role of PTX3 in promoting the first wave of synaptogenesis, and show that interplay of TSP1 and PTX3 sets the proper balance between synaptic growth and synapse function in the developing brain.
ER  - 

TY  - JOUR
TI  - Abstracts 544 - 1089
JO  - American Journal of Transplantation
VL  - 4
IS  - s8
SN  - 9780470654613
UR  - https://doi.org/10.1111/j.1600-6135.2004.0480b.x
DO  - doi:10.1111/j.1600-6135.2004.0480b.x
SP  - 308
EP  - 456
PY  - 2004
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - The FEBS Journal
VL  - 275
IS  - s1
SN  - 9780470654613
UR  - https://doi.org/10.1111/j.1742-4658.2008.06448.x
DO  - doi:10.1111/j.1742-4658.2008.06448.x
SP  - 99
EP  - 437
PY  - 2008
ER  - 

TY  - JOUR
TI  - II Joint Meeting of the German Society for Immunology (DGfl) and the Italian Society of Immunology, Clinical Immunology and Allergology (SIICA), 10–13 September, 2019, Munich, Germany
JO  - European Journal of Immunology
JA  - Eur. J. Immunol.
VL  - 49
IS  - S1
SN  - 9780470654613
UR  - https://doi.org/10.1002/eji.201970300
DO  - doi:10.1002/eji.201970300
SP  - 1
EP  - 306
PY  - 2019
ER  - 
